Genetic in situ engineering of myeloid regulatory cells controls inflammation in autoimmunity.

ABSTRACT: The ability of myeloid regulatory cells (MRCs) to control immune responses and to promote tolerance has prompted enormous interest in exploiting them therapeutically to treat inflammation, autoimmunity, or to improve outcomes in transplantation. While immunomodulatory small-molecule compounds and antibodies have provided relief for some patients, the dosing entails high systemic drug exposures and thus increased risk of off-target adverse effects. More recently, MRC-based cell-therapy products have entered clinical testing for tolerance induction. However, the elaborate and expensive protocols currently required to manufacture engineered MRCs ex vivo put this approach beyond the reach of many patients who might benefit. A solution could be to directly program MRCs in vivo. Here we describe

SUBMITTER: Parayath NN 

PROVIDER: S-EPMC8599636 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature